Axel Haverich

Axel Haverich (born March 9, 1953 in Lemgo) is a German cardiac surgeon.

Axel Haverich (2007)

Biography

Haverich completed his Abitur at the Barntrup Gymnasium in 1972. He studied medicine at the Medizinische Hochschule Hannover (MHH) and graduated in 1978.[1] One year later he received his M.D. title (promotion). During his work as an assistant surgeon he spend time as a research assistant at the Department of Cardiovascular Surgery der Stanford University.[1] In 1985 he became Senior Surgeon (Oberarzt) at the Clinic for Cardiac, Thoracic, and Vascular Surgery at the MHH. His habilitation was completed in 1987. From 1993 to 1996 he worked as the Director for heart and vascular surgery at the Kiel University.[1] In 1996 he returned to the MHH as medical director of Cardiac, Thoracic, Transplant and Vascular Surgery.[2]

Work

Much of Haverich’s work is focused on tissue engineering and development of implantable organs, specifically for the heart and vascular system. In 2006 his team reported on the transplantation of heart valves in two children (11 and 13 years old) done in 2002; the heart valves originated from donors, were decellularized, and then reseeded with autologous stem cells so that they would continue to grow.[3] Haverich's aim is eventually to rebuild the heart by tissue engineering "from ourselves".[4]

In 1996 Haverich founded the Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO) to develop bioengineered tissue for the heart.[4] In 2006 Haverich founded a private company, Corlife, to produce decellularized heart halves.

Hypothesis on development of arteriosclerosis

In 2017 Haverich presented a new hypothesis about the pathogenesis of arteriosclerosis.[5] While the potential role of infection and inflammation had been discussed for decades, Haverich noted that only specific arteries were subject to development of arteriosclerotic plaques. He postulated that the formation of plaques is not from inside the vessel, but the result of inflammation of the feeding vessels (vasa vasorum) of arteries that becoming inflamed compromising the integrity of the arterial wall. He noted that arteries with thin walls not having vasa vasorum do not develop arteriosclerosis. He postulated that the damage by inflamed vasa vasorum leads to cell death within the wall and subsequent plaques formation. Vasa vasorum inflammation can be caused by viruses, bacteria, and fine dust among others. According to his view this concept conforms to observations that cardiac infarctions are more common when influenza has occurred or fine particles have been inhaled.[6]

Memberships and editorships

(selection)

Awards

(selection)

References
  1. Medizinische Hochschule Hannover: Prof. Dr. Dr. h. c. A. Haverich (Biography, in German)
  2. MHH: Cardiac, Thoracic, Transplant and Vascular Surgery
  3. Serghei Cebotari, Artur Lichtenberg, Igor Tudorache, Andres Hilfiker, Heike Mertsching, Rainer Leyh, Thomas Breymann, Klaus Kallenbach, Liviu Maniuc, Aurel Batrinac, Oleg Repin, Oxana Maliga, Anatol Ciubotaru, Axel Haverich (July 3, 2006). "Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells". Circulation. Retrieved January 21, 2017.CS1 maint: multiple names: authors list (link)
  4. Barry Shurlock (May 12, 2009). "Pioneer in Cardiology: Axel Haverich, MD, PhD" (PDF). Circulation. doi:10.1161/CIRCULATIONAHA.109.192202. Retrieved January 21, 2017.
  5. Axel Haverich (January 16, 2017). "A Surgeon's View on the Pathogenesis of Atherosclerosis". Circulation. 135 (3): 205–207. doi:10.1161/circulationaha.116.025407. PMID 28093492.
  6. "MHH News release January 17, 2017". Archived from the original on January 18, 2017. Retrieved January 20, 2017.
  7. Membership Leopoldina
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.